Biotech RadarJobs updated

COMPANY

Boehringer Ingelheim

boehringer-ingelheim.com ↗

FDA-approved therapeutic company FDA-cleared device company Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Interstitial Lung Diseases Obesity Non-small Cell Lung Cancer Heart Failure Chronic Kidney Disease Neuroendocrine Neoplasms Glioma Hepatic Impairment Neoplasm Metastasis Metabolic Dysfunction Associated Steatohepatitis Lung Cancer, Non-squamous, Non-small Cell Systemic Lupus Erythematosus Liver Fibrosis Bronchiectasis Diabetic Retinopathy Macular Edema Geographic Atrophy Carcinoma, Squamous Cell of Head and Neck (HNSCC) Melanoma Diabetic Macular Edema Small Cell Lung Carcinoma Systemic Sclerosis Familial Pulmonary Fibrosis Interstitial Lung Abnormalities Metabolic Dysfunction-associated Steatotic Liver Disease Type 2 Diabetes Type 2 Diabetes Mellitus Hypertension Cardiovascular Diseases Liver Cirrhosis Idiopathic Inflammatory Myopathies KRAS Mutation Solid Tumors Metastatic Breast Cancer Metastatic Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Adenocarcinoma Colorectal Cancer

2,297Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies source ↗
  2. Trial start Phase 3: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight source ↗
  3. Trial start Phase 3: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight source ↗
  4. Trial start Phase 1: A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer source ↗
  5. Trial start Phase 3: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease source ↗
  6. Trial start Phase 1/Phase 2: A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) source ↗
  7. Trial start Phase 1: A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours) source ↗
  8. Trial start Phase 3: FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression source ↗
  9. Trial start Phase 1: A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or Overweight source ↗
  10. Trial start Phase 3: A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar source ↗
  11. Trial start Phase 3: A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis source ↗
  12. Trial start Phase 1: A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or Overweight source ↗
  13. Trial start Phase 1: A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contra source ↗
  14. Trial start Phase 3: DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy source ↗
  15. Trial start Phase 1/Phase 2: A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated source ↗
  16. Trial start Phase 1: A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated source ↗
  17. Trial start Phase 2: A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) source ↗
  18. Trial start Phase 2: A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) source ↗
  19. Trial start Phase 3: A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) source ↗
  20. Trial start Phase 3: A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis source ↗
  21. Trial start Phase 3: Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations source ↗
  22. Partnership Partnership / licensing: upfront €640M paid by the company to the licensor (in-licensing; not money received), announced Oct 30, 2025. Source: company release on GlobeNewswire. source ↗
  23. Trial start Phase 3: A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases source ↗
  24. Trial start Phase 1: A Study to Test How BI 1819479 is Taken up and Processed by the Body source ↗
  25. Trial start Phase 3: EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease source ↗

Showing 25 of 51 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Clinical trials (lead sponsor) Showing 50 of 2,297

RecordTitlePhaseStatusStartPrimary completion
NCT07195695Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsPhase 3RecruitingJan 16, 2026Feb 26, 2032 (estimated)
NCT06132113DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine CancersPhase 1Active, not recruitingJan 22, 2024Oct 9, 2027 (estimated)
NCT07656792A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the BloodPhase 1TerminatedJul 17, 2026Sep 23, 2026 (actual)
NCT05916313A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3Phase 1RecruitingJan 30, 2024Aug 9, 2027 (estimated)
NCT07023354A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver ProblemsPhase 1RecruitingJul 17, 2025Dec 23, 2026 (estimated)
NCT04886804Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)Phase 1Active, not recruitingJul 2, 2021Dec 30, 2026 (estimated)
NCT02342717Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male SubjectsPhase 1CompletedJan 29, 2015Mar 24, 2015 (actual)
NCT07526194A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are ToleratedPhase 1CompletedApr 22, 2026Sep 30, 2026 (actual)
NCT06806592A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic DiseasesPhase 3Active, not recruitingSep 13, 2025Jul 17, 2027 (estimated)
NCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPhase 3Not yet recruitingNov 7, 2026Jun 25, 2028 (estimated)
NCT06935370A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartPhase 3RecruitingMay 20, 2025Feb 4, 2029 (estimated)
NCT06531824EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)Phase 3Active, not recruitingAug 30, 2024Dec 31, 2026 (estimated)
NCT07851103A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced CancerPhase 1Not yet recruitingOct 26, 2026Sep 3, 2030 (estimated)
NCT07540988FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionPhase 3RecruitingSep 17, 2026Dec 5, 2028 (estimated)
NCT06632457LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisPhase 3RecruitingNov 12, 2024Jun 5, 2029 (estimated)
NCT07693231A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Japanese Healthy People and Japanese People With Obesity or OverweightPhase 1Active, not recruitingJul 21, 2026Dec 22, 2026 (estimated)
NCT06151574Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentPhase 3Active, not recruitingFeb 9, 2024Dec 10, 2026 (estimated)
NCT07409181A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)Phase 2RecruitingApr 20, 2026Feb 4, 2029 (estimated)
NCT06632444LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisPhase 3RecruitingOct 14, 2024Dec 27, 2031 (estimated)
NCT06872892The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPhase 3RecruitingJun 9, 2025Jun 15, 2027 (estimated)
NCT06321302A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyPhase 2Active, not recruitingMay 15, 2024Mar 5, 2027 (estimated)
NCT06424288A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailurePhase 3RecruitingJun 17, 2024May 22, 2028 (estimated)
NCT06962839A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaPhase 2RecruitingJun 5, 2025Sep 1, 2027 (estimated)
NCT06769048A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic AtrophyPhase 2Active, not recruitingJan 31, 2025Dec 22, 2026 (estimated)
NCT05068102A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabPhase 1Active, not recruitingMar 3, 2022Jan 22, 2026 (actual)
NCT07553429A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are ToleratedPhase 1/Phase 2RecruitingMay 14, 2026Mar 23, 2027 (estimated)
NCT06077500DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerPhase 1Active, not recruitingFeb 14, 2024Mar 31, 2027 (estimated)
NCT06077864A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)Phase 3CompletedNov 20, 2023Jun 1, 2026 (actual)
NCT07708493A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or OverweightPhase 1Active, not recruitingAug 24, 2026Oct 14, 2026 (estimated)
NCT05155332A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)Phase 1SuspendedMar 28, 2022Dec 13, 2027 (estimated)
NCT07065617A Study to Test How BI 1819479 is Taken up and Processed by the BodyPhase 1TerminatedAug 4, 2025Oct 4, 2025 (actual)
NCT05471856A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)Phase 1RecruitingFeb 24, 2023Sep 13, 2028 (estimated)
NCT07497087A Study to Test Whether Nerandomilast Helps People With Systemic SclerosisPhase 3RecruitingJul 27, 2026Feb 26, 2030 (estimated)
NCT07201922A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary FibrosisPhase 3RecruitingFeb 10, 2026May 14, 2029 (estimated)
NCT07850063ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseasePhase 3Not yet recruitingOct 23, 2026Apr 29, 2029 (estimated)
NCT07744152A Study to Test How Well Different Doses of BI 3822971 Are Tolerated by People With Advanced Cancer (Solid Tumours)Phase 1RecruitingSep 21, 2026Jan 15, 2030 (estimated)
NCT07754461A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPhase 3RecruitingAug 24, 2026Jan 17, 2028 (estimated)
NCT07064473EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePhase 3RecruitingJul 22, 2025Dec 14, 2029 (estimated)
NCT07850050SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightPhase 3Not yet recruitingOct 31, 2026Jul 26, 2028 (estimated)
NCT06926660A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney DiseasePhase 2CompletedJul 18, 2025Aug 14, 2026 (actual)
NCT07325526A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)Phase 2RecruitingFeb 27, 2026Aug 5, 2027 (estimated)
NCT07789015A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory MyopathiesPhase 3Not yet recruitingNov 9, 2026Mar 21, 2030 (estimated)
NCT04973163A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS MutationPhase 1Active, not recruitingSep 9, 2021Nov 29, 2026 (estimated)
NCT06324357Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadPhase 1/Phase 2RecruitingJun 28, 2024Jan 8, 2029 (estimated)
NCT06806852A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AlonePhase 1Active, not recruitingMay 14, 2025Aug 31, 2027 (estimated)
NCT07843940A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)Phase 1/Phase 2Not yet recruitingOct 5, 2026Apr 17, 2030 (estimated)
NCT07220083A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)Phase 3RecruitingFeb 16, 2026Dec 27, 2028 (estimated)
NCT06238622A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastPhase 3Active, not recruitingMay 6, 2024Apr 28, 2027 (estimated)
NCT07544654DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard ChemotherapyPhase 3RecruitingJul 10, 2026Dec 13, 2029 (estimated)
NCT04111458A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Phase 1Active, not recruitingNov 4, 2019Mar 31, 2027 (estimated)
Feedback